Publications
Filters: First Letter Of Keyword is D [Clear All Filters]
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy." Nat Commun 11, no. 1 (2020): 6410.
"A new Bayesian joint model for longitudinal count data with many zeros, intermittent missingness, and dropout with applications to HIV prevention trials." Stat Med 38, no. 30 (2019): 5565-5586.
"Semiparametric sieve maximum likelihood estimation under cure model with partly interval censored and left truncated data for application to spontaneous abortion." Lifetime Data Anal 25, no. 3 (2019): 507-528.
"Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups." J Biopharm Stat 29, no. 4 (2019): 625-634.
"Improving efficiency of parameter estimation in case-cohort studies with multivariate failure time data." Biometrics 73, no. 3 (2017): 1042-1052.
"Single-nucleotide resolution analysis of nucleotide excision repair of ribosomal DNA in humans and mice." J Biol Chem 294, no. 1 (2019): 210-217.
"Single-nucleotide resolution analysis of nucleotide excision repair of ribosomal DNA in humans and mice." J Biol Chem 294, no. 1 (2019): 210-217.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs." Nat Commun 10, no. 1 (2019): 309.
"Confident difference criterion: a new Bayesian differentially expressed gene selection algorithm with applications." BMC Bioinformatics 16 (2015): 245.
"Seamless Phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat 26, no. 5 (2016): 912-23.
"FMEM: functional mixed effects modeling for the analysis of longitudinal white matter Tract data." Neuroimage 84 (2014): 753-64.
"Seamless Phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat 26, no. 5 (2016): 912-23.
"A longitudinal functional analysis framework for analysis of white matter tract statistics." Inf Process Med Imaging 23 (2013): 220-31.
"A longitudinal functional analysis framework for analysis of white matter tract statistics." Inf Process Med Imaging 23 (2013): 220-31.
"A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
"Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
"Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
"A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
"Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome." J Biopharm Stat 24, no. 2 (2014): 429-42.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"Across-Platform Imputation of DNA Methylation Levels Incorporating Nonlocal Information Using Penalized Functional Regression." Genet Epidemiol 40, no. 4 (2016): 333-40.
"Response to reader reaction." Biometrics 71, no. 1 (2015): 267-273.
"A robust method for estimating optimal treatment regimes." Biometrics 68, no. 4 (2012): 1010-8.
"Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching." Lifetime Data Anal 20, no. 1 (2014): 76-105.
" Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
"Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
"Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer." Biometrics 67, no. 4 (2011): 1422-33.
"A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring." J Biopharm Stat 24, no. 2 (2014): 229-53.
"Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment." J Biopharm Stat 26, no. 2 (2016): 269-79.
"Hypothesis testing at the extremes: fast and robust association for high-throughput data." Biostatistics 16, no. 3 (2015): 611-25.
"An Expectation Maximization algorithm for fitting the generalized odds-rate model to interval censored data." Stat Med 36, no. 7 (2017): 1157-1171.
"Empirical pathway analysis, without permutation." Biostatistics 14, no. 3 (2013): 573-85.
"Semiparametric inference for a two-stage outcome-dependent sampling design with interval-censored failure time data." Lifetime Data Anal 26, no. 1 (2020): 85-108.
"Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome." Biostatistics 12, no. 3 (2011): 521-34.
"Empirical pathway analysis, without permutation." Biostatistics 14, no. 3 (2013): 573-85.
"Multivariate varying coefficient models for DTI tract statistics." Med Image Comput Comput Assist Interv 13, no. Pt 1 (2010): 690-7.
"Bayesian influence measures for joint models for longitudinal and survival data." Biometrics 68, no. 3 (2012): 954-64.
"Multivariate varying coefficient models for DTI tract statistics." Med Image Comput Comput Assist Interv 13, no. Pt 1 (2010): 690-7.
"Time-dependent classification accuracy curve under marker-dependent sampling." Biom J 58, no. 4 (2016): 974-92.
"FADTTS: functional analysis of diffusion tensor tract statistics." Neuroimage 56, no. 3 (2011): 1412-25.
"A model-based conditional power assessment for decision making in randomized controlled trial studies." Stat Med 36, no. 30 (2017): 4765-4776.
"On model selections for repeated measurement data in clinical studies." Stat Med 34, no. 10 (2015): 1621-33.
"